31 Aug

Eli Lilly’s New Products in 2Q17

WRITTEN BY Mike Benson

New products from Eli Lilly

Eli Lilly & Co.’s (LLY) product portfolio includes new products like Basaglar, Cyramza, Jardiance, Lartruvo, Olumiant, Taltz, and Trulicity. The chart below shows the revenues of each of these new products since 3Q15. The details about these products and their performance during 2Q17 follow.

Eli Lilly’s New Products in 2Q17


Basaglar is an insulin glargine injection to control blood sugar levels in diabetes patients. The drug was launched in the US market in December 2016. Basaglar’s sales totaled $86.6 million during 2Q17—its US sales totaled $60 million and its international sales totaled $27 million.


Cyramza is an oncology drug for the treatment of metastatic non-small cell lung cancer, metastatic colorectal cancer, and advanced gastric cancer. Cyramza’s sales totaled $186.3 million during 2Q17, reflecting 27% growth compared to 2Q16, driven by increased demand in Japan and Europe.


Jardiance is a drug used to lower blood sugar levels in patients with Type 2 diabetes. The drug is developed as part of the diabetes alliance between Eli Lilly and Boehringer Ingelheim. Jardiance’s sales reached $103.2 million during 2Q17, driven by its strong performance in the US and international markets.


Lartruvo is a drug for the treatment of patients with advanced soft tissue sarcoma. The drug was launched in the US and European markets during 4Q16. Lartruvo’s sales totaled $47.4 million during 2Q17.


Taltz is a drug for the treatment of plaque psoriasis. The drug was launched in the US in April 2016 and in Europe in July 2016. Taltz’s sales reached $138.7 million during 2Q17, including its US sales of $124.0 million.


Trulicity is a drug for improving blood sugar levels in patients with Type 2 diabetes. Trulicity’s sales totaled $480.2 million during 2Q17, representing growth exceeding 100% compared to $201.3 million during 2Q16. This growth was driven by strong performance in the US markets.

To divest company-specific risks, investors can consider the Vanguard Healthcare ETF (VHT) which holds 2.2% of its total assets in Eli Lilly (LLY). VHT also holds 4.9% in Merck & Co. (MRK), 3.1% in Medtronic Plc (MDT), and 2.1% in Allergan Plc (AGN).

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.